OneSource
OneSource Specialty Pharma is an Indian publicly listed specialty pharmaceutical CDMO providing end-to-end development and manufacturing services across drug-device combinations, complex injectables, biologics, and soft gelatin capsules to global pharmaceutical and biotechnology companies.
- Company typePublic
- Founded1990
- HeadquartersBengaluru, India
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What OneSource does
OneSource Specialty Pharma Limited is a publicly listed Indian specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services across four core technology platforms: drug-device combinations, complex injectables, biologics (microbial and mammalian cell line), and soft gelatin capsules. The company was established in 2021 as a Strides Pharma Group initiative under founder Arun Kumar and completed its IPO on Indian exchanges (BSE and NSE) in January 2025. Headquartered in Bengaluru with five state-of-the-art manufacturing facilities approved by FDA, MHRA, ANVISA, TGA, WHO and MCC, OneSource serves global pharmaceutical and biotechnology companies seeking integrated drug substance and drug product manufacturing under a single quality system. The company employs over 1,600 professionals including more than 100 techno-commercial experts, with named customers including Dr. Reddy's, Hikma, Formycon, Xbrane Biopharma and Orbicular.
The company's technical capabilities span high-concentration biologic formulations via the HILOPRO platform (licensed from Bhami Research Lab, validated across six commercial molecules at 100-250 mg/mL), drug-device combination assembly across 9 device formats with 20+ flexible assembly stations, lyophilization using QbD-led PAT-driven cycles, and integrated GLP-1 peptide formulation and analytical development. Infrastructure includes 550,000 ft² of dedicated biologics manufacturing space, capacity to produce 2.4 billion softgel capsules annually, and over 20 automatic and semi-automatic assembly lines for prefilled syringes, pen injectors and autoinjectors. The company tracks 35 approved ANDAs, 40+ commercialized US products and 200+ regulatory inspections cleared, including 18 in the past 24 months.
OneSource generates revenue through project-based CDMO contracts and commercial manufacturing services, with pricing not publicly disclosed and determined by scope, volume and complexity. The go-to-market is direct B2B enterprise sales supported by techno-commercial experts, event-driven engagement at industry conferences such as CPHI Frankfurt, and a content library of technical whitepapers and webinars. Customer segments are horizontally split between enterprise pharmaceutical companies (primary) and biotechnology companies (primary), with secondary use cases in GLP-1 and peptide therapeutics developers and biosimilar developers. Distribution is entirely B2B with no retail or consumer channels, and the customer base spans the United States, India, the United Kingdom, Canada, Brazil and Saudi Arabia. Leadership is drawn from major pharma companies including Ranbaxy, Sun Pharma, Steriscience, Moderna, Roche, Syngene and Fujifilm Diosynth.
OneSource firmographics
Firmographics- Name
- OneSource
- Legal name
- OneSource Specialty Pharma Limited
- Website
- https://onesourcecdmo.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- OneSource Specialty Pharma is an Indian publicly listed specialty pharmaceutical CDMO providing end-to-end development and manufacturing services across drug-device combinations, complex injectables, biologics, and soft gelatin capsules to global pharmaceutical and biotechnology companies.
- Ownership category
- akta.pro rank
OneSource industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where OneSource is headquartered
LocationHeadquarters
- HQ city
- Bengaluru
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
OneSource business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Full-service CDMO providing end-to-end development and manufacturing services across multiple technology platforms. Revenue generated through project-based contracts for drug development, analytical services, and commercial manufacturing. Services span early-stage development through commercialization and lifecycle management.
- Commercial Manufacturing: Manufacturing services for approved drug products including sterile injectables, biologics, drug-device combinations, and soft gelatin capsules. Revenue from commercial supply of drug products.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
OneSource product offering
Product offeringCore offering
OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) that provides end-to-end drug development and manufacturing services across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company offers integrated pharmaceutical services from early-stage formulation development through analytical characterization, GMP manufacturing, regulatory support, and commercial supply. Services are delivered to global pharmaceutical and biotech clients through five state-of-the-art facilities in Bengaluru, India, approved by FDA, MHRA, ANVISA, TGA, WHO, and MCC.
Product overview
OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) offering end-to-end capabilities across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company provides integrated services from early-stage development through commercialization, encompassing formulation development, analytical characterization, GMP manufacturing, and regulatory support. Key offerings include the HILOPRO formulation platform for high-concentration subcutaneous biologics, GLP-1 peptide development services, lyophilization services, and advanced analytical characterization. With five state-of-the-art facilities in Bengaluru, India, OneSource serves pharmaceutical and biotech companies globally seeking integrated CDMO partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug-Device Combinations Comprehensive development and manufacturing of specialized drug-device combination products including prefilled syringes with/without safety devices, dial and push variable/fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. Currently handling 9 device platforms/formats for pharmaceutical and biotech clients.
- Complex Injectables (Sterile Injectables) Development and manufacturing of complex sterile injectables including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections with over 25 years of domain experience. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.
- Biologics CDMO Services End-to-end biologics solutions including development and manufacture of microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products with integrated drug substance and drug product cGMP manufacturing. Supported by 550,000 ft² of biologics manufacturing space.
- Soft Gelatin Capsules Mastery in soft gelatin capsule technologies including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories with capacity of 2.4 billion capsules annually across versatile shapes and sizes.
- HILOPRO Formulation Platform High-concentration formulation platform for subcutaneous biologics delivery that solves the concentration-viscosity challenge, enabling protein concentrations of 100-250 mg/mL while maintaining syringeability. Patented by Bhami Research Lab, accessed by OneSource through strategic partnership, validated across six commercial molecules.
- GLP-1 Peptide Development Services Integrated formulation and analytical development for GLP-1 peptide therapeutics including stability optimization, solubility enhancement, aggregation control, viscosity management, and device compatibility for diabetes and obesity treatments.
- Lyophilization Services Development, optimization, scale-up and transfer of lyophilization cycles for challenging formulations including QbD-led approach with PAT-driven endpoints and thermal characterization for scalable, regulatory-ready freeze-drying processes.
- Analytical Characterization Services Advanced analytical characterization including LC-MS, SEC-MALS, surface plasmon resonance (SPR), peptide mapping, cell-based bioassays, and stability-indicating methods for defining Critical Quality Attributes and supporting CMC documentation.
Quantifiable outcome
- 35 approved ANDAs and 19 commercialized drug products in the United States
- +3 more outcomes
Companies that use OneSource
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
OneSource technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
OneSource partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Formycon AGcoreStrategic manufacturing partnership for biosimilars. OneSource will provide manufacturing capabilities for Formycon's biosimilar pipeline targeting global markets.
- HikmacorePartnership to commercialize generic version of Ozempic (Semaglutide Injection) in Saudi Arabia. OneSource provides manufacturing and regulatory support.
- Xbrane BiopharmacoreBiosimilars manufacturing partnership for global markets. OneSource and Xbrane collaborate on development and manufacturing of biosimilar products.
- Bhami Research LabcoreStrategic partnership giving OneSource access to the HILOPRO formulation platform, a patented high-concentration biologic formulation technology validated across six commercial molecules.
- Dr. Reddy's LaboratoriescoreCDMO partnership where OneSource supports Dr. Reddy's manufacturing needs. Dr. Reddy's received Health Canada Approval for Generic Semaglutide Injection with OneSource's support.
- OrbicularcoreOrbicular's Partner secured tentative U.S. ANDA approval for generic Ozempic with OneSource as CDMO partner providing manufacturing support.
- ICICI SecuritiesminorProvided fairness opinion for the Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) in 2025.
Scale indicators12 records
Recent moves10 records
Expansion highlights5 records
OneSource competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Switzerland-based global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable in CDMO business model and biologics/drug product capabilities, but at substantially larger scale and broader geographic footprint.
- WuXi AppTec / WuXi STA: China-based global CDMO offering end-to-end services across small molecules, biologics, and cell/gene therapies. Comparable in integrated CDMO model and biologics capabilities, though operating in a different geography.
- Catalent: US-headquartered global CDMO with leading positions in softgel capsules, sterile injectables, and biologics drug product. Closely comparable in softgel (OneSource produces 2.4B capsules/year) and drug-device combination capabilities.
Direct peers
- Syngene International: India-based publicly listed CDMO offering end-to-end drug discovery, development, and manufacturing services across small molecules and biologics. Direct comparable in geography, scale, and integrated CDMO model serving global pharma and biotech customers.
- Jubilant Pharmova: India-based pharmaceutical company with CDMO operations across sterile injectables, APIs, and radiopharmaceuticals. Direct comparable in injectables and biologics contract manufacturing.
- Sai Life Sciences: India-based CDMO offering discovery, development, and manufacturing services for small molecules and biologics. Comparable in geographic footprint, full-service CDMO model, and biotech/pharma customer base.
- Suven Pharmaceuticals: India-based CDMO focused on contract development and manufacturing of APIs and intermediates. Comparable in India-based operations serving global pharma customers, though more concentrated in small molecules.
- Piramal Pharma Solutions: India-headquartered CDMO with capabilities across sterile injectables, biologics, and oral solids; competes directly with OneSource in complex injectables and drug substance/drug product integration for global pharma customers.
- Laurus Labs: India-based pharmaceutical company with a growing CDMO segment offering API, formulation, and biologics services. Comparable in geographic base, customer profile, and integrated CDMO capabilities.
Emerging players
- Aurobindo Pharma: India-based vertically integrated pharmaceutical company with growing injectable and biosimilar manufacturing capabilities. Comparable in sterile injectables and biosimilars development focus, though primarily a generic manufacturer rather than pure-play CDMO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
OneSource social profiles
Digital presenceOneSource compliance and trust
Trust signalCompliance6 records
OneSource financial estimates
Financial estimateRevenue estimate
Valuation estimate
OneSource leadership team
Management profileNumber of profiles
Profiles15 records
OneSource subsidiaries and ownership
Company hierarchySubsidiaries7 records
OneSource funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OneSource M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OneSource
What does OneSource do?
OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) that provides end-to-end drug development and manufacturing services across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company offers integrated pharmaceutical services from early-stage formulation development through analytical characterization, GMP manufacturing, regulatory support, and commercial supply. Services are delivered to global pharmaceutical and biotech clients through five state-of-the-art facilities in Bengaluru, India, approved by FDA, MHRA, ANVISA, TGA, WHO, and MCC.
Is OneSource a public or private company?
OneSource is a public company. It is classified as public and is currently operating.
When was OneSource founded?
OneSource was founded in 1990. It employs 501 to 1,000 people.
Where is OneSource based?
OneSource is headquartered in Bengaluru, India, in the Asia region.
How does OneSource make money?
Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing.
Who are OneSource's main competitors?
Broad incumbents on record are Lonza Group, WuXi AppTec / WuXi STA and Catalent. Direct peers are Syngene International, Jubilant Pharmova, Sai Life Sciences, Suven Pharmaceuticals, Piramal Pharma Solutions and Laurus Labs. Aurobindo Pharma is listed as an emerging player.
Does OneSource have an API?
No public API is recorded for OneSource.
What industry is OneSource in?
OneSource's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.